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Abstract
Background: To construct a short prostate cancer radiation late toxicity (PCRT) questionnaire
with health-related quality-of-life (HRQoL) domains.
Methods:  The PCRT was developed by item generation, questionnaire construction (n = 7
experts, n = 8 focus group patients), pilot testing (n = 37), item reduction (n = 100), reliability
testing (n = 237), and validity testing (n = 274).
Results:  Reliability of the three item-reduced subscales demonstrated intraclass correlation
coefficients (CC) of 0.811 (GU), 0.842 (GI), and 0.740 (sexual). Discriminant validity demonstrated
Pearson CC of 0.449 (GU-GI), 0.200 (sexual-GU), and 0.09 (sexual-GI). Content validity
correlations between PCRT-PCQoL were 0.35–0.78, PCRT-FACT-G© were 0.19–0.39, and PCRT-
SF-36® were 0.03–0.34.
Conclusion: We successfully generated a PCRT HRQoL questionnaire including subscales with
very good psychometric properties.
Background
The concept of therapeutic ratio is the relationship
between tumor control and significant toxicities of treat-
ment. The acute and long-term treatment-related morbid-
ities associated with the various prostate cancer treatment
options, such as radical prostatectomy (RP), external-
beam radiation therapy (RT), permanent brachytherapy
seed implant, temporary high-dose rate (HDR) brachy-
therapy implant, and hormonal manipulation, can be sig-
nificant [1]. Therefore, the concept of therapeutic ratio is
important in defining the trade-off that patients accept for
cure/control vs. harm. Strategies incorporating radiation
dose escalation (total dose and dose per fraction escala-
tion) for improving local control require improvements
in patient immobilization, prostate imaging/targeting,
treatment delivery and verification. This increased level of
technical sophistication is necessary in order to optimize
the therapeutic ratio by adequately treating the tumor vol-
ume(s) of interest while respecting the tolerance of nor-
mal tissues such as rectum, bladder, penile bulb and the
bilateral femoral heads [2]. Dose and dose-per-fraction
escalation strategies to improve the prognosis of localized
and locally advanced prostate cancer require a greater
emphasis on the assessment and treatment of radiation-
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induced late effects. Better methods of documenting late
rectal, bladder, and sexual toxicity are required to comple-
ment tumor control data such as the biochemical-free,
disease-free, and overall survival endpoints to ensure the
therapeutic ratio is being optimized through these treat-
ment innovations.
Late rectal, bladder and sexual effects have been histori-
cally graded using toxicity scales such as the Radiation
Therapy Oncology Group (RTOG)/European Organiza-
tion for Research and Treatment of Cancer (EORTC) Late
Radiation Morbidity Scoring Scheme or the Late Effects
Normal Tissue Task Force – Subjective, Objective, Man-
agement, and Analytic (LENT-SOMA) scales [3-5]. These
scales are usually easy to administer; however, they are
limited in the type and complexity of the information cap-
tured. In addition, impact on health-related quality of life
(HRQoL) of these side effects is not measured by these
scales, (i.e. these scales do not measure the impact or
bother to the patient of a specific symptom). Potentially,
patients may have high symptom grade and low impact/
bother or conversely can have low symptom grade and
high impact/bother. Various HRQoL questionnaires (e.g.
PCQoL, Expanded Prostate Index Composite [EPIC©])
have been constructed to assess HRQoL of patients with
prostate cancer before, during and/or after various pros-
tate cancer treatments (surgery, radiation, hormones, and
brachytherapy) [6,7]. However, an easily administered
questionnaire that can capture the late effects of RT has
not been constructed [8,9].
The goal of this investigation was to construct a short
prostate cancer radiation late-toxicity HRQoL instrument
corresponding to relevant symptoms as identified by
patients, radiation oncologists and the medical literature.
This questionnaire was to be concise, easy to administer,
and relate directly to the common late toxicities of pros-
tate radiotherapy as assessed by patients, experts, and the
medical literature of other existing HRQoL questionnaires
and toxicity scales. Derivation of appropriate HRQoL sub-
scales was to be performed though a process of item
grouping and reduction. Various gastrointestinal (GI),
genitourinary (GU) and sexual HRQoL subscales were to
be generated and subsequently tested for ease of adminis-
tration, reliability and validity.
Methods
Study questionnaires
Prostate Cancer Radiation Late Toxicity (PCRT) Questionnaire
The development of the PCRT questionnaire was the cen-
tral focus of this research and the final questionnaire is
included in Appendix 1 (see Additional file 1). The final
PCRT is a 29-item instrument evaluating symptoms relat-
ing to the late effects of RT after treatment for prostate can-
cer. This study was designed to test 3 toxicity/QOL
question subsets for the PCRT: GI Symptoms/Bother
(Questions 1–12), GU Symptoms/Bother (Questions 13–
23), and Sexual (Questions 24–28).
Prostate Cancer Quality of Life (PC-QoL) Questionnaire
The version one PC-QoL is a 52-item self-administered,
prostate cancer health-related quality-of-life instrument
relating to QOL issues for prostate cancer patients treated
with a variety of local therapies (brachytherapy, RP, and
external-beam RT)[6]. This questionnaire has ten HRQoL
scales that can be self-administered in multiple settings
(i.e. research vs. clinical). The subscales incorporated
within the PC-QoL include: Urinary Function/Role Activ-
ity Limitations/Bother, Sexual Function/Role Activity
Limitations/Bother, Bowel Function/Role Activity Limita-
tions/Bother, and Cancer Worry.
Functional Assessment Cancer Therapy-General (FACT-G©)
The version four FACT-G© is a 27-item general cancer
health-related quality-of-life instrument with 5 QOL sub-
scales which can be used in conjunction with modular
instruments such as the FACT-P©[10]. Further refinements
to the FACT-G© questionnaire have resulted in the current
27-item version four questionnaire with the following five
subscales: Physical Well-Being, Social-Family Well-Being,
Emotional Well-Being, Functional Well-Being, and Over-
all Well-Being
Medical Outcomes Study Short Form – 36 (SF-36®)
The version one SF-36® is a 36-item (short form health sur-
vey) general HRQoL with 8 subscales [11-13]. The SF-36®
was found to be reliable and valid in a variety of clinical/
research settings and patient populations, both in the
MOS study and in subsequent investigations. The eight
health domains that the SF-36® measures are: Health Per-
ception, Physical Functioning, Role Limits in Physical
Functioning, Role Limits in Emotional Health, Social
Functioning, Mental Health, Pain, Energy and Fatigue.
Patient feedback/ease of use form
Patients' understanding of the PCRT, the ease of use form,
and any other suggestions were obtained by having all
patients complete a short questionnaire assessing the fol-
lowing domains: easy to understand questions, question
format, adequate response range, and additional com-
ments.
Study population
Five groups of patients were studied for the various stages
of assessment of the PCRT questionnaire (1. question-
naire construction focus group (n = 8), 2. questionnaire
pilot study – patient feedback (n = 37), 3. item reduction
(n = 100), 4. reliability testing (n = 237), and 5. validity
testing (n = 271). A total of 479 patients were approached
for various aspects of the study with 379 (79%) patientsHealth and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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agreeing to participate. All five populations used the same
inclusion and exclusion criteria as described below.
The study population consisted of male patients of any
age who had previously undergone radical external beam
RT or radical brachytherapy for prostate cancer at the Lon-
don Regional Cancer Program (LRCP). Patients with any
T stage, PSA, and Gleason score were eligible for the study.
Participants were selected from the GU follow-up clinics
provided they met all required inclusion criteria. The
study involved those individuals who had completed
radiation at least one full year prior to their follow-up
appointment. Patients were excluded from the study if
they have had previous surgery (i.e. RP or orchidectomy),
chemotherapy, or any clinical or radiological evidence of
metastases. Patients with PSA failure, previous or current
hormonal therapy, or TURP procedures were allowed in
the study. Patients must have been able to complete ques-
tionnaires in English.
Construction of PCRT questionnaire
This goal of this study was to construct a brief < 30-item
questionnaire assessing late toxicities relating to prostate
cancer radiotherapy. After a systematic review and assess-
ment of the world literature (PUBMED abstracts of pros-
tate cancer HRQoL questionnaires and their respective
reference lists as well as published prostate cancer HRQoL
review article reference lists), a list of potentially relevant
items was obtained. Questionnaire items were chosen and
constructed on a 5-point Likert scale. A total of twenty-
nine questions were constructed assessing the GU, GI, and
sexual late toxicities in terms of symptom severity and its
associated bother to the patient. Questionnaire items were
constructed with wording consistent with an eighth grade
level.
Consultation with several LRCP staff radiation and medi-
cal oncologists at the LRCP (n = 7) was performed to eval-
uate the appropriateness of the initial questionnaire, and
its face validity. After further editing, the questionnaire
was assessed and completed by 8 prostate cancer patients
attending a local prostate cancer support group for feed-
back on content and wording. No demographic informa-
tion was available in this cohort due to privacy concerns.
All necessary final revisions were made at this point in
order to improve the questionnaire prior to general imple-
mentation.
Pilot testing of PCRT questionnaire
A convenience sample of 37 patients was obtained at the
LRCP consistent with the study inclusion/exclusion crite-
ria. Patient demographic information was collected and
each patient filled in a patient feedback/ease of use ques-
tionnaire in conjunction with a PCRT questionnaire. The
PCRT questionnaire was administered to this cohort of
patients in order to determine patient's perceptions of
whether the content and format of the questionnaires
were easy to understand. In addition, subjects were asked
to comment on whether any additional items should be
included.
Item reduction of PCRT questionnaire
A PCRT questionnaire and a self-addressed, self-stamped
envelope were provided to eligible patients. A sample of
100 patients was planned for this phase of the study. Each
participant was given one day to complete the PCRT
instrument and then returned the package to the study
investigators. Item reduction was performed by the dele-
tion of low variability items. If > 90% of responses were
identical for all symptom and bother items in a specific
domain, all questions were deleted from the appropriate
scales. For example, if both the diarrhea "symptom" and
"bother" question were both found to have low heteroge-
neity of response, and then both questions were deleted
from their appropriate scales. If only one of the questions
was found to have low variability, neither question was
deleted at this stage of the analysis; however, the potential
impact of their deletion was assessed by Cronbach sensi-
tivity analysis [14].
Cronbach coefficient sensitivity analysis for deleted items
was used to determine if any of the remaining items
should be deleted. Cronbach alpha values of greater than
or equal to 0.7 are considered to demonstrate good inter-
nal subscale consistency. Values of 0.5 to 0.7 are consid-
ered to be acceptable with values under 0.5 considered to
be an unacceptable level of internal consistency. There-
fore, for scales with less than 0.7 Cronbach alpha statis-
tics, sensitivity analysis was used to determine the optimal
number of items in the scale to maximize the alpha coef-
ficient. No imputation of missing values was performed;
therefore, only subscales with complete data were used for
Cronbach's analysis.
Reliability testing of PCRT questionnaire
The test-retest reliability of the PCRT questionnaire was
determined by comparing the consistency of answers
between a first self-administration of the PCRT question-
naire and a second self-administration two weeks later on
eligible study patients. Two weeks after the initial ques-
tionnaire was completed, a reminder phone call was
placed to all patients prompting them to complete the sec-
ond questionnaire and to then send it back to LRCP.
Patient demographic statistics and questionnaire response
descriptive statistics were both calculated. Raw subscale
scores were used with no linear transformation for this
analysis. Intraclass correlation coefficients (one way, two-
way fixed effects model, and two-way random effects
model) and 95% confidence intervals for all PCRT sub-
scales were calculated to assess the reliability of the ques-Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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tionnaire. No imputation of missing values was
performed; therefore, only subscales with complete data
were used for initial intraclass correlation coefficient anal-
ysis. A second analysis including subscale scores with ≥
50% data completion was also performed. Intraclass cor-
relation coefficients of > 0.7 were considered to be indic-
ative of an excellent reliability correlation. Intraclass
correlations of 0.4 – 0.7 were considered to be acceptable.
Validity testing of PCRT questionnaire
Individuals fitting the study parameters were provided
with questionnaire validation packages. The package con-
sisted of an envelope with a set of four questionnaires
(PCRT, PC-QoL, FACT-G©, and SF-36®) given in random
order (block randomized in groups of 24 = 4 × 3 × 2 × 1)
and a self-addressed stamped envelope. The participant
was given one day to complete the questions and then was
to return the package to the LRCP. The data collected from
these questionnaires was used to assess the validity of the
PCRT questionnaire. Subscale scores were calculated and
subjected to a linear transformation to a 0 (low HRQoL,
high symptoms) to 100 (high HRQoL, low symptoms).
To assess discriminant validity, Pearson correlation coeffi-
cients were calculated among all the subscales of the PCRT
questionnaire. No imputation of missing values was per-
formed; therefore, only subscales with complete data were
used for Pearson correlation coefficient analysis. To assess
construct validity, Pearson correlation coefficients were
calculated between all subscales of the PCRT question-
naire and the PC-QoL; PCRT and FACT-G©; PCRT and SF-
36®. To further assess construct validity, a comparison of
PCRT scores between brachytherapy and external-beam
patients was performed using Student's t-test (as brachy-
therapy and external-beam RT patients would be expected
to have different toxicity profiles).
Sample size considerations
The sample size for the initial pilot study of 37 patients
was based on a convenience sample. The sample size cal-
culation for the internal consistency evaluation of 100
patients (37 pilot + 63 additional patients) was based on
the confidence interval formula [N = (zα/2 /CI)2+3, where
N = sample size, zα/2 = 1.96 for 95% confidence interval CI
is the correlation coefficient confidence interval]. There-
fore, for a confidence interval of 0.2, the required sample
size was calculated to be 99 patients.
The anticipated sample size for the combined reliability
and validation study will be approximately 272 com-
pleted questionnaire sets in order to detect statistically sig-
nificant correlations of 0.30 or higher (0.00 – null
hypothesis). A sample size of 191 individuals was calcu-
lated; however, the sample size was increased by 50% in
order to take into account potential missing data from
questionnaire non-compliance. This calculation has also
taken multiple statistical testing into account with a Bon-
ferroni correction calculation (alpha = 0.05/140 =
0.00035). All statistics were performed on the SAS/STAT®
(SAS Institute®, Cary NC, USA) system.
Results
Construction of PCRT questionnaire
After a medical literature review and discussion with
expert GU oncologists an initial questionnaire of twenty-
nine 5-point Likert scale items was created. The final list
of items included questions encompassing the GU (fre-
quency/nocturia, dysuria, hematuria, and incontinence),
GI (hematochezia, diarrhea, pelvic pain, bowel control,
and tenesmus), and sexual (impotency, libido, and inter-
est) domains. Questionnaire items either related to the
quantitative degree of impairment of the particular
"symptom" or to the qualitative "bother" experienced by
patients for a particular symptom.
All 8 patients approached to fill out an initial question-
naire during the London Prostate Cancer Support Group
meeting completed questionnaires. Most questionnaire
items demonstrated some variability in response other
than hematuria (symptoms/bother) and incontinence
(symptom only). All other questionnaire items had signif-
icantly greater variability in response. A questionnaire was
constructed after all patient, expert, and medical literature
consultation was complete (Appendix 1 [see Additional
file 1]).
Pilot testing of PCRT questionnaire
Of 40 patients who were eligible and who agreed to par-
ticipate in the study, 37 (93%) completed a PCRT ques-
tionnaire and patient feedback form. Mean patient age
was 74 years (range 61 – 82 years). Pre-treatment param-
eters were as follows. Mean PSA was 14.9 ng/ml (range 2.0
– 68.0). T staging was T1 (10 patients, 27%), T2 (21
patients, 57%), and T3 (6 patients, 16%). Median
Gleason grade was 6/10 with 9 (24%) patients with grade
2–5, 13 (35%) patients with grade 6, 10 (27%) patients
with grade 7, and 5 (14%) patients with grade 8–10.
Median prostate dose to the prostate was 66 Gray (Gy,
range 63 – 76Gy) with 10/37 (27%) patients receiving
pelvic RT to regional nodes and prostate (median dose 46
Gy, range 44 – 50 Gy). No patients were treated with
brachytherapy.
Only 14 (1.3%) among 1073 (37 questionnaires × 29
questions per questionnaire) possible responses were
missing. All missing items were related to sexual question-
naire items. Thirty-three (89%) of thirty-seven pilot study
patients filled out the patient feedback form after comple-
tion of the PCRT questionnaire. All patients reported that
the questionnaire items and format were easy to under-Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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stand (feedback form question 1,3). Of the 33 respond-
ents, 31 (94%) patients found the questionnaire
comprehensive, with 1 (3%) patient not responding, and
1 (3%) patient recommending the addition of a question
assessing fatigue. No pilot study patients had any further
comments or potential changes to recommend.
Item reduction of PCRT questionnaire
One hundred and twenty-six patients were consented for
completion of PCRT questionnaires for item reduction
with 100 (79%) patients completing the PCRT. Of
patients filling out the questionnaire, mean patient age of
respondents was 75 years (range 61 – 82 years). Pre-treat-
ment parameters were as follows. Mean PSA was 15.1 ng/
ml (range 2.0 – 68.0). Prostate cancer T staging was T1 (20
patients, 20%), T2 (59 patients, 59%), T3 (18 patients,
18%) and Tx (3 patients, 3%). Median Gleason grade was
6/10 with 49 (49%) patients with grade 2–6, 34 (34%)
patients with grade 7, and 16 (16%) patients with grade
8–10. Median prostate dose was 69.4 Gy (range 52.5 –
76.0 Gy) with 27/100 (27%) patients receiving pelvic RT
to regional nodes and prostate (median dose 46 Gy, range
44 – 50.4 Gy). No patients were treated with brachyther-
apy. No demographic information was collected on non-
responders due to privacy/ethics concerns.
Of 100 patients who filled out questionnaires, 77 (77%)
had no missing items. Eleven patients (11%) had only
one missing item and a further 11 (11%) patients had 2–
6 missing items. One patient (1%) has 18 missing items.
Of a possible 2900 (100 questionnaires × 29 questions
per questionnaire) responses, 71 (2.4%) were missing.
Eighteen of 1200 (1.5%) GI responses, 10 of 1100 (0.9%)
GU, and 43 of 600 (7.2%) sexual responses were missing.
In terms of question response extremes; frequency (q13, n
= 2), nocturia (q14, n = 4), impotency (q24, n = 1), libido
(q26, n = 2), and sexual contentment (q28, n = 4) had less
than ten percent #1 (least affected) responses. All sexual
questions (q24-q28) had greater than ten percent #5
(most affected) responses. Conversely, none of the other
questions (q1-q23) had greater than five percent #5
responses. The following questions were found to have
limited heterogeneity (> 90% in one response item): dys-
uria symptoms and bother (q16-q18), hematuria symp-
toms and bother (q19-q20), and incontinence II
symptom and bother (q22-q23). The first incontinence
symptom question (q21) had sufficient heterogeneity of
response (#1 – 74%, #2 – 15%, #3 – 2%, #4 – 6%, #5 –
1%) to maintain the entire incontinence question set in
the GU subscale. Therefore, the dysuria and hematuria
questions sets were deleted from further consideration
within the GU subscales.
Cronbach coefficient analysis using three subscales dem-
onstrated raw coefficients for GI (0.859), GU (0.529), and
sexual (0.700) subscales (Table 1). No significant
improvements in coefficients were found with the dele-
tion of any questionnaire item from their respective sub-
scale except for libido symptom (q26, 0.700 to 0.756).
However, removal of the corresponding bother question
would decrease the Cronbach's coefficient (0.700 to
0.574). Therefore, no further questions were deleted from
their respective subscales. Splitting the GI and GU
domains into separate symptom and bother subscales
diminished the Cronbach's coefficients in all cases: GI
symptoms (0.859 to 0.729), GI bother (0.859 to 0.777),
GU symptoms (0.529 to 0.358), and GU bother (0.529 to
0.190). Therefore, three subscales were used for further
reliability and validity testing.
A Cronbach alpha sensitivity analysis of a four-item GU
scale (all frequency/nocturia and incontinence I symp-
toms) versus a six-item scale (all frequency/nocturia and
incontinence items) versus an 11-item scale (all potential
GU items) was performed to identify the optimal number
of scale items (Table 2). The maximum raw Cronbach
coefficient was found in the scale including only ques-
tions that were previously identified as having acceptable
heterogeneity of response (4-item GU scale). Additional
items did not improve internal consistency to the GU
scale (Cronbach alpha 0.545 (4-item) versus 0.529 (6-
item) and 0.515 (11-item).
Reliability testing of PCRT questionnaire
Three hundred and forty-two patients were approached
regarding the reliability study with 274 (80%) consenting
to participate in the study. Two hundred and seventy-one
patients filled out the PCRT test questionnaire, with 237
(87%) patients filling out the subsequent retest question-
naire. Of patients consenting to the study, mean patient
age of respondents was 73.8 years (range 56 – 88 years).
Pretreatment parameters were as follows. Mean PSA was
13.3 ng/ml (range 2.0 – 144.0). Prostate cancer T staging
was T1 (78 patients, 28.5%), T2 (142 patients, 51.8%), T3
(40 patients, 14.6%) and Tx (14 patients, 5.1%). Median
Gleason score was 6/10 with 142 (51.8%) patients with
grade 2–6, 81 (29.6%) patients with score 7, and 38
(13.9%) patients with score 8–10. Median prostate dose
was 70.0 Gy (range 50.0 – 78.0 Gy) with 10/232 (4.3%)
patients receiving pelvic RT (median dose 46 Gy, range 44
– 50.4 Gy). Thirty-eight patients were treated with brach-
ytherapy. No demographic information was collected on
non-responders due to privacy/ethics concerns.
Calculation of the one-way and two-way intraclass corre-
lation coefficients (ICC) was performed (Table 3). Esti-
mates of GI, GU, and sexual ICC for the no-missing test-
retest reliability condition were 0.842, 0.811, and 0.740,Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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respectively. The corresponding values for ICC when less
than or equal to 50% missing data is allowed are 0.784,
0.779, and 0.729. Therefore, in general test-retest reliabil-
ity was found to be very good in both the complete data
and partially complete data settings.
Validity testing of PCRT questionnaire
Three hundred and forty-two patients were approached
regarding the study at LRCP of which 274 (80%) agreed to
participate. The PCRT test questionnaire was filled out by
271 individuals, and the PC-QoL (n = 272), FACT-G© (n =
271), SF-36® (n = 272) questionnaires were filled out by
similar numbers. Patient demographics and radiation sta-
tistics were identical to the reliability testing cohort as all
patients that consented to the reliability testing study also
completed the validity questionnaire set.
Mean PCRT subscale transformed scores were 89.6 (GI),
66.9 (GU), and 42.0 (sexual). Mean PCQoL domain
scores ranged from a low of 20.1 (sexual function) to a
high of 94.5 (bowel limitations) with a possible range of
0 (severely affected) to 100 (not affected). Mean FACT-G©
domain scores ranged from 20.8 (emotional domain) to
24.6 (physical domain) with a range of 0 (severely
affected) to 28 (not affected). Mean SF-36® domain scores
ranged from 56.1 (role physical) to 85.6 (social function-
Table 1: Item reduction analysis – Cronbach coefficient alpha analysis (3 subscales)
Deleted Questionnaire Item GI (n = 93) GU (n = 97) Sexual (n = 85)
q1 0.848
q2 0.851
q3 0.853
q4 0.853
q5 0.841
q6 0.851
q7 0.848
q8 0.848
q9 0.851
q10 0.843
q11 0.848
q12 0.831
q13 0.481
q14 0.502
q15 0.458
q21 0.268
q22 0.497
q23 0.528
q24 0.699
q25 0.588
q26 0.756
q27 0.574
q28 0.560
Raw Cronbach Coefficient alpha 0.859 0.529 0.700
Table 2: Item reduction analysis – Cronbach sensitivity analysis for GU domain
Deleted Question # Domain GU 4-item GU 6-item GU 11-item
q13 Frequency (s) 0.485 0.481 0.470
q14 Nocturia (s) 0.518 0.502 0.488
q15 Frequency/Nocturia (b) 0.328 0.364 0.381
q16 Dysuria I (s) 0.518
q17 Dysuria II (s) 0.518
q18 Dysuria (b) 0.504
q19 Hematuria (s) 0.511
q20 Hematuria (b) 0.520
q21 Incontinence I (s) 0.533 0.489 0.463
q22 Incontinence II (s) 0.497 0.471
q23 Incontinence (b) 0.529 0.504
Raw Cronbach Coefficient 
Alpha
0.545 0.529 0.515Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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ing) with a range of 0 (severely affected) to 100 (not
affected).
The highest intra-PCRT domain Pearson correlation exists
with GI-GU at 0.449. Lower correlations existed between
the sexual and GU (0.200) and GI (0.098) domains. Pear-
son correlation between the PCRT and PCQoL domains
are presented in table 4. Significant correlations between
analogous domains were demonstrated. GI PCRT correla-
tions with bowel-related PCQoL domains ranged from
0.61 to 0.78. GU PCRT correlations with urinary-related
PCQoL domains ranged from 0.35 to 0.64. Sexual PCRT
correlations with related PCQoL domains ranged from
0.42 to 0.66. Correlation between the GI PCRT and FACT-
G© domains ranged from 0.19 to 0.34 (Table 5). GU PCRT
correlations with FACT-G© domains ranged from 0.20 to
0.39. Correlation between the PCRT sexual domain and
the FACT-G© domains ranged from 0.21 to 0.35. Correla-
tion between the GI PCRT and SF-36® domains ranged
from 0.03 to 0.27 (Table 6). GU PCRT correlations with
Table 3: Reliability Analysis – Intraclass Correlation Coefficient Test-Retest Analysis
Domain ICC No Missing Data (95% CI) ≤ 50% Missing Data (95% CI)
GI one way 0.842 (0.792–0.881) 0.784 (0.728–0.829)
two way (random) 0.842 (0.281–0.881) 0.784 (0.252–0.828)
two way (fixed) 0.843 (0.794–0.881) 0.784 (0.728–0.825)
GU one way 0.812 (0.760–0.853) 0.779 (0.723–0.825)
two way (random) 0.811 (0.767–0.852) 0.779 (0.789–0.824)
two way (fixed) 0.811 (0.759–0.853) 0.778 (0.723–0.824)
Sexual one way 0.740 (0.664–0.801) 0.729 (0.660–0.787)
two way (random) 0.740 (0.294–0.801) 0.729 (0.263–0.787)
two way (fixed) 0.740 (0.663–0.801) 0.729 (0.659–0.787)
Random = random effects model; Fixed = fixed effects model.
Table 4: Validity analysis – Pearson correlation coefficient content validity analysis (PCQoL)
PCQoL Domain GI PCRT Sexual PCRT GU PCRT
0.205 0.24 0.54
Urinary Function p = 0.002 p = 0.0004 p < 0.0001
n = 216 n = 205 n = 243
0.08 0.280 0.35
Urinary Limitations p = 0.224 p < 0.0001 p < 0.0001
n = 218 n = 207 n = 244
0.29 0.280 0.64
Urinary Bother p < 0.0001 p < 0.0001 p < 0.0001
n = 215 n = 205 n = 240
0.04 0.420 0.09
Sexual Function p = 0.531 p < 0.0001 p = 0.018
n = 207 n = 207 n = 232
0.18 0.480 0.18
Sexual Limitations p = 0.009 p < 0.0001 p = 0.005
n = 204 n = 205 n = 227
0.25 0.660 0.15
Sexual Bother p = 0.0004 p < 0.0001 p = 0.025
n = 203 n = 205 n = 225
0.78 0.20 0.45
Bowel Function p < 0.0001 p = 0.004 p < 0.0001
n = 219 n = 205 n = 244
0.61 0.27 0.38
Bowel Limitations p < 0.0001 p < 0.0001 p < 0.0001
n = 219 n = 208 n = -246
0.73 0.25 0.46
Bowel Bother p < 0.0001 p = 0.0003 p < 0.0001
n = 219 n = 206 n = 245
0.16 0.12 0.16
Cancer Worry p = 0.016 p = 0.074 p = 0.011
n = 220 n = 206 n = 246Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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SF-36® domains ranged from 0.16 to 0.34. Correlation
between the PCRT sexual domain and the SF-36® domains
ranged from 0.14 to 0.55.
Higher mean domain scores were found in the brachy-
therapy cohort when compared to the external-beam radi-
ation population. Mean difference scores of 4.13, 3.50,
and 3.63 were found for the GI, sexual, and GU domains
respectively. Only the GI domain was found to have a sta-
tistically significant difference in score with a p-value of
0.02.
Discussion
As with any symptom or side effect of treatment, there are
quantitative and qualitative aspects to the potential
impairment. The level of impairment (quantitative symp-
tom scale) to the patient can range from no impairment
to severe impairment. The potential impact of the symp-
tom (qualitative bother scale) to the patient can also vary
from no bother to severe bother. The PCRT questionnaire
was constructed to capture both symptom and bother
concepts for each of the late sexual, GI, and GU impair-
ments represented in the questionnaire. The question-
Table 5: Validity analysis – Pearson coefficient content validity analysis (FACT-G©)
FACT-G© Domain GI PCRT Sexual PCRT GU PCRT
Physical 0.34 0.34 0.39
p < 0.0001 p < 0.0001 p < 0.0001
n = 220 n = 205 n = 243
Social/Family 0.19 0.21 0.20
p = 0.005 p = 0.003 p = 0.002
n = 219 n = 203 n = 242
Emotional 0.20 0.22 0.24
p = 0.002 p = 0.002 p = 0.0002
n = 219 n = 206 n = 244
Functional 0.21 0.27 0.29
p = 0.0001 p < 0.0001 p < 0.0001
n = 222 n = 208 n = 247
Total 0.32 0.35 0.31
p < 0.0001 p < 0.0001 p < 0.0001
n = 216 n = 201 n = 239
Table 6: Validity analysis – Pearson correlation coefficient content analysis (SF-36®)
SF-36® Domain GI PCRT Sexual PCRT GU PCRT
0.12 0.55 0.16
Physical Functioning p = 0.06 p = 0.027 p = 0.013
n = 220 n = 205 n = 244
0.18 0.22 0.20
Role Physical p = 0.007 p = 0.002 p = 0.0018
n = 219 n = 207 n = 242
0.21 0.17 0.31
Bodily Pain p = 0.002 p = 0.014 p < 0.0001
n = 219 n = 207 n = 245
0.26 0.14 0.23
General Health p < 0.0001 p = 0.05 p = 0.0003
n = 220 n = 206 n = 245
0.25 0.26 0.26
Validity p = 0.0002 p = 0.0002 p < 0.0001
n = 221 n = 209 n = 248
0.27 0.24 0.34
Social Functioning p < 0.0001 p = 0.0004 p < 0.0001
n = 219 n = 206 n = 246
0.03 0.21 0.19
Role Emotional p = 0.63 p = 0.0004 p = 0.004
n = 213 n = 198 n = 237
0.26 0.48 0.22
Mental Health p = 0.0002 p = 0.01 p = 0.0004
n = 221 n = 209 n = 248Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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naire was constructed so that if a patient responded that
they did not experience a specific symptom, they would
skip the corresponding "bother" question because it was
irrelevant to that patient. A five-point scale was used in
each of the questionnaire items in order to balance suffi-
cient discriminative symptom and bother response levels
with easy administration and reporting properties. In
addition, cancer clinicians are familiar with the concept of
5-point toxicity scales ranging from low to high impair-
ment. Commonly used instruments include the NCICTC,
RTOG Radiation Toxicity Criteria, and the Eastern Coop-
erative Oncology Group (ECOG) Performance Status
scale.
During the initial questionnaire construction process,
eight prostate cancer patients conforming to the study
population filled out questionnaires. The primary role of
the initial group of eight patients was to give initial ques-
tionnaire feedback to the investigator for improvements
in wording and content. Due to the limited number of ini-
tial patients looking at the questionnaire, no formal con-
clusions regarding comprehensiveness and ease of use
could be made. No changes in the questionnaire items
were made prior to further pilot testing and item reduc-
tion analysis. Patients were asked to assess the various
symptoms and corresponding bother item over the last
four weeks prior to filling out the questionnaire. This was
done in order to reduce the impact of variability of filling
out the questionnaire on a non-representative day.
Because most toxicities occur in the order of several
months to many years after RT, the four week time period
was felt to be appropriate. In addition, follow-up visits
after prostate cancer radiation occur usually in three to
twelve month intervals.
Response rates for both the PCRT questionnaire and the
corresponding patient feedback form were high at 93%
and 89%, respectively. The pilot study also allowed an
assessment of missing items. The missing item rate was
found to be low at 1.3% of all possible responses. All
missing responses dealt with the sexual domain of the
PCRT, likely a reflection of the personal nature of the
questions. However, over 90% of all sexual domain ques-
tions were answered by the respondents, likely due to the
general non-explicit nature of the questions and that only
six questions of the 29 dealt with this issue. In addition,
the pilot cohort could be considered to be a select group
of motivated patients, which would lead to generally
higher questionnaire and questionnaire item response
rates. All pilot study patients reported that the question-
naire content and format were easy to understand. The
response rate for the item reduction cohort PCRT ques-
tionnaire was 79% compared to 93% in the initial pilot
cohort. This potentially reflects a less motivated group of
patients and/or less intensive monitoring during data col-
lection given a larger study population as compared to the
pilot cohort. The assessment of missing items demon-
strated a low overall missing item response rate of 2.4%
with the majority of missing items coming from the sexual
question set (7.2%) versus the GI (1.5%) or GU (0.9%)
question sets. Therefore, the observation of a dispropor-
tionate level of missing data with the sexual question set
was confirmed in the larger item reduction cohort.
Ninety-three percent of patients "never" experienced dys-
uria and 97% "never" had hematuria. Dysuria is a com-
mon acute side-effect of radiation treatment which
usually subsides after completion of therapy. Gross hema-
turia (visible to the naked eye) is an uncommon late side-
effect of RT. The finding of hematuria and dysuria as low
variability items in a late toxicity questionnaire was an
expected finding. In general, clinically relevant and signif-
icant late toxicities such as hematuria, which occur infre-
quently, may be better assessed in a late toxicity scale
(RTOG, LENT-SOMA) as opposed to a HRQoL instru-
ment. In terms of the integration of these items into the
GU HRQoL scale of the PCRT it was felt it would be inap-
propriate given the lack of discriminative ability of these
two question sets within the population of patients being
studied.
For the subscale analysis, the GI scale had very good inter-
nal consistency (0.859), the sexual scale demonstrated
good consistency (0.700), and the GU scale demonstrated
fair consistency (0.529). An assessment of the various
options for a 4-, 6-, and 12-item GU scale demonstrated a
slight advantage to the shorter 4-item scale on Cronbach
sensitivity analysis. The shorter 4-item scale corresponds
to the 4 items that had significant heterogeneity of
response: Frequency symptoms, Nocturia symptoms, Fre-
quency/nocturia bother, and Incontinence (frequency of
leaking urine) symptoms. The decreased internal consist-
ency of the GU scale may potentially be a result of dimin-
ished variability compared to the sexual and GI scales in
this study population (majority treated with external-
beam RT with minority brachytherapy). In addition, fur-
ther refinement of the GU questionnaire items may
improve internal consistency. Potentially, using more
than five question responses for the GU questionnaire
items may increase the variability of response and the dis-
criminative ability of the scale.
Further reliability testing (test-retest) and validity analyses
were performed to evaluate the characteristics of the 4-
item GU scale in order to make a final determination of its
appropriateness as a HRQoL scale. Therefore, the final
PCRT questionnaire contains 29-items with GI (12-item),
GU (4-item), and sexual (5-item) subdomains, and 7
individual dysuria, hematuria, and incontinence pad/dia-
per symptom and bother items. In addition, q29 sepa-Health and Quality of Life Outcomes 2007, 5:29 http://www.hqlo.com/content/5/1/29
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rately assesses level of sexual activity but is not included in
the sexual score. The reliability test-retest analysis had an
excellent overall 80% response rate that will likely not
cause any issues regarding selection bias and the general-
isability of the questionnaire. All reliability intra-class cor-
relations were greater than or equal to 0.7 for all domains
either with no missing data or < 50% missing data.
Slightly higher reliability coefficients were seen in the
analysis of patients with no missing data due to a highly
consistent dataset. However, the differences in reliability
coefficient due to missing data were small and in the
range of 0.011 to 0.059. The one-way intraclass correla-
tion coefficient is likely the best estimate for reliability
given the random nature of patients fully completing the
domain of interest. Therefore, the PCRT domains demon-
strated stable and consistent mean and median scores in
all domains with reasonable overall and individual sub-
scale response rates. Reliability, as assessed by the test-
retest intraclass correlation coefficient, was acceptable for
all three subscales. Therefore, validation proceeded for all
three PCRT subscales.
The overall response rate for all patients approached
regarding the validation study was acceptable at 80%. Of
the 274 patients who completed the four questionnaire
validation sets, over 99% of the questionnaires were com-
pleted (PCRT n = 271, PCQoL n = 272, FACT-G© n = 271,
and SF-36® n = 272). This population demonstrated differ-
ent levels of HRQoL for different domains of the PCRT
questionnaire. It appears that these patients have overall
good GI, intermediate GU, and poor sexual functioning as
measured by the PCRT instrument. Poor sexual function
scores were also seen in the PCQoL questionnaire. In
addition, this study population demonstrated low average
vitality and physical scores on the SF-36® questionnaire.
The FACT-G© mean scores were relatively homogeneous
with no domain being more affected than the others. The
PCRT questionnaire demonstrated discriminative validity
in terms of the fact that there was some low-level correla-
tion between all three measures ranging from 0.098 to
0.449. Therefore, the three subscales measure different
but somewhat related (i.e. relating to radiation toxicities)
domains. Further content validity was demonstrated by
the progressive lower correlation between the subscales of
the PCRT with the prostate cancer questionnaire
(PCQoL), the general cancer questionnaire (FACT-G©),
and a general health questionnaire (SF-36®).
The limitations of the study include the following: the
PCRT is validated in external-beam RT and brachytherapy
populations only (surgery, chemotherapy populations
not studied), the PCRT is only validated for the 4 week
time frame with the PCRT not designed for the acute
phase of radiation (either concurrently with RT and/or <
6 months after RT complete), the PRCT subscales have not
been cross-validated against existing late toxicity scales, or
other toxicity risk factors such as DVH parameters, and
responsiveness of PCRT subscales over time has not been
determined. In addition, limited psychometric testing in
the brachytherapy population may have excluded the dys-
uria question pair (symptom and bother) from the final
GU subscales.
Future work in the development of the PCRT question-
naire can include an assessment of other populations that
receive external-beam RT for prostate cancer would gener-
ate additional information regarding the PCRT question-
naire. Unstudied populations include patients who have
had previous TURP or RP (adjuvant or salvage setting)
and patients who may receive concurrent chemotherapy
with radiotherapy. These populations may potentially
express greater levels of late toxicity due to the multimo-
dality nature of the treatments given. Study of subpopula-
tions of RT patients (nodal RT vs. prostate alone,
moderately high vs. high dose RT) may also be performed.
An acute version of the questionnaire has been developed
and will be tested in an appropriate patient population.
Integration of the PCRT questionnaire into clinical trials
assessing novel radiation techniques, dose escalation and
dose per fraction escalation can be performed. Assessment
of new normal-tissue sparing technologies such as IMRT
and helical tomotherapy require validated toxicity and
HRQoL instruments to assess potential improvements.
Potential randomized phase II or III studies could use the
PCRT as either a primary (phase I/II safety assessment) or
secondary (phase III superiority or equivalence trial) end-
point. Concurrent chemotherapy with agents such as tax-
anes may also become increasingly the focus of clinical
trials. Assessment of late effects will be necessary to con-
firm the safety of the combined management should effi-
cacy be detected. Correlation with existing late toxicity
scales and dosimetric/DVH parameters could potentially
be another avenue for investigation. Routine intermittent
administration of this questionnaire in the setting of post-
radiation therapy follow-up could serve as a screening
questionnaire to detect negative quality-of-life effects due
to the late toxicities of prostate radiation therapy. Identi-
fied individuals with large changes in late toxicity quality
of life scores can be subsequently subjected to appropriate
diagnostic, therapeutic, and educational programs to mit-
igate these negative quality-of-life effects.
Conclusion
We successfully generated a PCRT HRQoL questionnaire
including genitourinary, gastrointestinal, and sexual sub-
scales. This research has created a psychometrically relia-
ble and valid short questionnaire specifically assessing the
HRQoL related to the late effects of prostate radiation
therapy. This instrument should have important futurePublish with BioMed Central    and   every 
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applications in the long-term clinical follow-up/triage of
radiation late effects. In addition, various clinical trial/
research opportunities exist in association with such a tar-
geted questionnaire.
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